1921
Volume 83, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus–infected persons in leishmaniasis-endemic areas. The standard treatment may not be effective and relapses are common. We report the case of a human immunodeficiency virus-1–infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.09-0594
2010-07-01
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/1/010.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0594&mimeType=html&fmt=ahah

References

  1. de La Rosa R, Pineda JA, Delgado J, , 2002. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40: 762767.[Crossref]
  2. Alvar J, Aparicio P, Aseffa A, , 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.[Crossref]
  3. Sundar S, , 2001. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849854.[Crossref]
  4. Sundar S, Rai M, , 2005. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 28212829.[Crossref]
  5. Troya J, Casquero A, Refoyo E, , 2008. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 40: 7880.[Crossref]
  6. Manfredi R, Marinacci G, Calza L, , 2008. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. Int J Antimicrob Agents 31: 590592.[Crossref]
  7. Soto J, Soto P, , 2006. Oral miltefosine to treat leishmaniasis. Biomedica (Bogota) 26: 207217.[Crossref]
  8. Davidson RN, den Boer M, Ritmeijer K, , 2009. Paromomycin. Trans R Soc Trop Med Hyg 103: 653660.[Crossref]
  9. Sundar S, Jha TK, Thakur CP, , 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 25712581.[Crossref]
  10. Jha TK, Olliaro P, Thakur CP, , 1998. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316: 12001205.[Crossref]
  11. Lafeuillade A, Chaffanjon P, Delbeke E, , 1992. Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med 92: 449.[Crossref]
  12. Chunge CN, Owate J, Pamba HO, , 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84: 221225.[Crossref]
  13. Thakur CP, Olliaro P, Gothoscar S, , 1992. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86: 615616.[Crossref]
  14. Thakur CP, Bhowmick S, Dolfi L, , 1995. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 89: 219223.[Crossref]
  15. Thakur CP, Kanyok TP, Pandey AK, , 2000. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94: 429431.[Crossref]
  16. Seaman J, Pryce D, Sondorp HE, , 1993. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 168: 715720.[Crossref]
  17. Pintado V, Martín-Rabadán P, Rivera ML, , 2001. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 5473.[Crossref]
  18. Davidson RN, , 1998. Practical guide for the treatment of leishmaniasis. Drugs 56: 10091018.[Crossref]
  19. Béchade D, Seurat L, Discamps G, , 1996. Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole. Rev Med Interne 17: 234237.[Crossref]
  20. Angarano G, Maggi P, Coppola SL, , 1998. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 17: 365367.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0594
Loading
/content/journals/10.4269/ajtmh.2010.09-0594
Loading

Data & Media loading...

  • Received : 05 Oct 2009
  • Accepted : 24 Nov 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error